Recent Updates
Recently added Catalysts
ORGO Positive Sentiment Score: 85/100

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Wednesday, April 3, 2024 2 min read
Key Takeaway: Organogenesis Holdings Inc. announced that the United States District Court for the Eastern District of New York dismissed all claims in a securities fraud case against the company. The court's ruling, granted with prejudice, allows Organogenesis to move forward without the weight of litigation. Chief Administrative and Legal Officer Lori Freedman expressed satisfaction with the decision, emphasizing the company's commitment to enhancing patient outcomes while reducing care costs.

Market Sentiment Analysis

POSITIVE FACTORS

  • The court ruling allows Organogenesis to move forward without the burden of a securities fraud case.
  • This outcome enables the company to focus on its mission to improve patient outcomes.
  • The ruling was granted with prejudice, which prevents future claims on this matter.

Full Press Release Details

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
April 3, 2024 at 7:30 AM EDT
CANTON, Mass., April 03, 2024
(GLOBE NEWSWIRE) Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports
Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company s motion to dismiss all claims asserted.
We are very pleased with the Court s decision, said Lori Freedman, Chief Administrative and Legal Officer for Organogenesis. We are
happy to have this behind us so we can continue to focus on our mission to substantially improve patient outcomes while lowering the overall cost of care.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc.
is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative
regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Inquiries: ICR Westwicke Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis communications@organo.com

Frequently Asked Questions

What was the recent court ruling involving Organogenesis?

A U.S. District Court dismissed all claims against Organogenesis with prejudice.

Who announced the favorable court ruling for Organogenesis?

Lori Freedman, Chief Administrative and Legal Officer, announced the ruling.

What is Organogenesis focused on?

The company specializes in regenerative medicine for wound care and sports medicine.

When was the court ruling announced?

The ruling was announced on April 3, 2024.

What are the future plans for Organogenesis after the ruling?

Organogenesis aims to focus on improving patient outcomes and reducing care costs.

Tags: ORGO Viatris Investor Conferences Healthcare Organogenesis securities fraud court ruling patient outcomes advanced wound care
Last updated: Apr 3, 2024